Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Relatlimab (Primary) ; Zanzalintinib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STELLAR-002
  • Sponsors Exelixis

    • Most Recent Events

    • 07 Feb 2023 According to an Exelixis media release, Exelixis has established a recommended dose of 100 mg for zanzalintinib in combination with nivolumab, and we have begun enrolling expansion cohorts for patients with clear cell RCC, The novel triplet combination of zanzalintinib and the fixed-dose combination of nivolumab and relatlimab has the potential to be used in multiple expansion cohorts
    • 18 Jan 2023 According to ClinicalTrials.gov record, one new treatment arm (Experimental: XL092 + Nivolumab + Relatlimab Dose-Escalation Cohorts) has been added into the study. Hence treatment arms has been changed from 6 to 7. and 4 new indication were added which includes Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma.
    • 18 Jan 2023 Planned number of patients changed from 826 to 1078.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top